相似文献
1
Biological therapies for spondyloarthritis.
Ther Adv Musculoskelet Dis. 2014 Jun;6(3):92-101. doi: 10.1177/1759720X14535512.
2
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.
Ther Adv Chronic Dis. 2015 Nov;6(6):328-38. doi: 10.1177/2040622315608647.
3
Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition.
Adv Ther. 2022 Apr;39(4):1490-1501. doi: 10.1007/s12325-022-02064-x. Epub 2022 Feb 24.
4
Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Rom J Ophthalmol. 2018 Apr-Jun;62(2):114-122.
5
Axial spondyloarthritis.
Nat Rev Dis Primers. 2015 Jul 9;1:15013. doi: 10.1038/nrdp.2015.13.
6
Impact of biological therapy on spondyloarthritis.
Eur J Clin Pharmacol. 2014 Sep;70(9):1021-7. doi: 10.1007/s00228-014-1706-x. Epub 2014 Jun 10.
7
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Qatar Med J. 2022 Jul 7;2022(3):29. doi: 10.5339/qmj.2022.29. eCollection 2022.
8
Biologic therapies in the spondyloarthritis: new opportunities, new challenges.
Curr Opin Rheumatol. 2003 Jul;15(4):394-407. doi: 10.1097/00002281-200307000-00005.
9
[Axial spondyloarthritis].
Vnitr Lek. 2018 Spring;64(2):108-116.
10
Emerging treatment options for spondyloarthritis.
Best Pract Res Clin Rheumatol. 2018 Jun;32(3):472-484. doi: 10.1016/j.berh.2019.01.014. Epub 2019 Feb 21.
引用本文的文献
1
Difficult-to-Treat Spondyloarthritis in Morocco: A Real-World Study.
Mediterr J Rheumatol. 2024 Dec 31;35(Suppl 3):549-556. doi: 10.31138/mjr.290124.dtt. eCollection 2024 Dec.
2
F-FDG positron emission tomography as a marker of disease activity and treatment response in ankylosing spondylitis and psoriatic arthritis.
Sci Rep. 2024 Aug 28;14(1):19907. doi: 10.1038/s41598-024-60669-4.
3
Analysis of gene expression profiles and protein-protein interaction networks in multiple tissues of systemic sclerosis.
BMC Med Genomics. 2019 Dec 27;12(1):199. doi: 10.1186/s12920-019-0632-2.
4
Disease-Modifying Effects of Long-Term and Continuous Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Spondyloarthritis.
Adv Pharmacol Sci. 2019 Jan 29;2019:5324170. doi: 10.1155/2019/5324170. eCollection 2019.
5
Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms.
Arthritis Care Res (Hoboken). 2019 Feb;71(2):323-330. doi: 10.1002/acr.23600.
6
Medical Treatment of Ankylosing Spondylitis.
Hip Pelvis. 2014 Sep;26(3):129-35. doi: 10.5371/hp.2014.26.3.129. Epub 2014 Sep 29.
7
Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.
Ther Adv Chronic Dis. 2015 Nov;6(6):328-38. doi: 10.1177/2040622315608647.
8
Safety Profile of Certolizumab Pegol in Patients with Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-Analysis.
Drug Saf. 2015 Oct;38(10):869-88. doi: 10.1007/s40264-015-0336-2.
9
Management of arthropathy in inflammatory bowel diseases.
Ther Adv Chronic Dis. 2015 Mar;6(2):65-77. doi: 10.1177/2040622314563929.
本文引用的文献
1
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).
Ann Rheum Dis. 2015 Jun;74(6):1051-7. doi: 10.1136/annrheumdis-2013-204963. Epub 2014 Feb 18.
2
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
Ann Rheum Dis. 2014 May;73(5):817-23. doi: 10.1136/annrheumdis-2013-204248. Epub 2014 Jan 3.
3
Methotrexate in psoriatic arthritis.
Bull Hosp Jt Dis (2013). 2013;71 Suppl 1:S41-5.
4
Certolizumab pegol in axial spondyloarthritis.
Expert Rev Clin Immunol. 2013 Dec;9(12):1161-72. doi: 10.1586/1744666X.2013.858859.
5
Long-term treatment with golimumab for severe uveitis.
Ocul Immunol Inflamm. 2014 Apr;22(2):90-5. doi: 10.3109/09273948.2013.844265. Epub 2013 Oct 21.
6
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential.
Ther Adv Musculoskelet Dis. 2013 Oct;5(5):277-85. doi: 10.1177/1759720X13501021.
7
Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
Expert Opin Biol Ther. 2013 Nov;13(11):1599-611. doi: 10.1517/14712598.2013.839653. Epub 2013 Sep 27.
8
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.
Lancet. 2013 Nov 23;382(9906):1705-13. doi: 10.1016/S0140-6736(13)61134-4. Epub 2013 Sep 13.
9
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Ann Rheum Dis. 2014 Jan;73(1):39-47. doi: 10.1136/annrheumdis-2013-204231. Epub 2013 Sep 6.
10
Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
Ann Rheum Dis. 2014 Jan;73(1):233-7. doi: 10.1136/annrheumdis-2013-203697. Epub 2013 Aug 13.
Zotero 插件